Nuvation Bio (US:NUVB) ZACKS·2026-03-02 23:35分组1 - Nuvation Bio Inc. reported a quarterly loss of $0.11 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.15 per share a year ago [1] - The company posted revenues of $41.87 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 52.63%, compared to revenues of $5.71 million in the same quarter last year [2] - Nuvation Bio has surpassed consensus revenue estimates four times over the last four quarters, although it has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed, losing about 34% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.05 on revenues of $48.34 million, and for the current fiscal year, it is -$0.33 on revenues of $197.35 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Nuvation Bio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]